IMNM Q4 2020 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$4M

Net Income

-$4M

EPS (Diluted)

$-0.40

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$319,000

Balance Sheet

Total Assets

$45M

Total Liabilities

$3M

Stockholders' Equity

$41M

Cash & Equivalents

$40M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$4M	-$3M	-41.0%
Net Income	-$4M	-$3M	-39.4%